US FDA Guidance Homes In On RnD Challenges For Rare Disease Drug Makers
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued a draft guidance document that seeks to advance and facilitate the development of medicines for preventing and treating rare diseases by discussing issues commonly encountered by orphan drug makers1.